The woman had no history of preexisting neurologic disease or recent travel, but she had had follicular non-Hodgkin B-cell lymphoma since 2011, which evolved into a diffuse large B-cell lymphoma despite immunochemotherapy
and corticosteroid treatment.
Scientists at the University of Southampton aim to bring patients with a common type of fast-growing cancer fresh hope with a new clinical trial that will investigate an experimental drug, in combination with immunochemotherapy
, in specific patients with diffuse large B-cell lymphoma (DLBCL), the university announced on Friday.
Hasselblom S, Hansson U, Olsson M (2010) High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
4) It appears that the prognosis of PB-DLBCL is generally comparable with that of nodal DLBCL and that standard treatment should consist of immunochemotherapy
with an anthracycline-based regimen and include consolidation with radiotherapy especially in stage IE patients.
Detection of minimal residual disease following induction immunochemotherapy
predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.
Use of interim [18F] fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy
Randomized controlled trial of the efficacy of adjuvant immunochemotherapy
and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur," International Journal of Clinical Oncology, vol.
They describe strategies of passive and active immunotherapy, improving immunotherapeutic responses using combinations of agents for immunochemotherapy
, and targeting strategies to defeat immune suppression.
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy
MatBA[R]-DLBCL assesses the presence of single biomarkers as well as genome complexity as measures of overall survival following front-line immunochemotherapy
Randomized, controlled study on adjuvant immunochemotherapy
with PSK in curatively resected colorectal cancer.
Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy
with interleukin 2, interferon alpha and 5-fluorouracil.